Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Plus Therapeutics (PSTV) Preferred Dividend Payments (2017 - 2019)

Plus Therapeutics has reported Preferred Dividend Payments over the past 5 years, most recently at $554000.0 for Q3 2019.

  • Quarterly Preferred Dividend Payments fell 77.72% to $554000.0 in Q3 2019 from the year-ago period, while the trailing twelve-month figure was $3.0 million through Dec 2019, down 52.95% year-over-year, with the annual reading at $554000.0 for FY2019, 77.72% down from the prior year.
  • Preferred Dividend Payments was $554000.0 for Q3 2019 at Plus Therapeutics, down from $2.5 million in the prior quarter.
  • Over five years, Preferred Dividend Payments peaked at $4.0 million in Q4 2017 and troughed at $554000.0 in Q3 2019.
  • The 4-year median for Preferred Dividend Payments is $1.6 million (2015), against an average of $1.9 million.
  • The largest YoY upside for Preferred Dividend Payments was 77.72% in 2019 against a maximum downside of 77.72% in 2019.
  • A 4-year view of Preferred Dividend Payments shows it stood at $661000.0 in 2015, then skyrocketed by 501.66% to $4.0 million in 2017, then tumbled by 37.47% to $2.5 million in 2018, then tumbled by 77.72% to $554000.0 in 2019.
  • Per Business Quant, the three most recent readings for PSTV's Preferred Dividend Payments are $554000.0 (Q3 2019), $2.5 million (Q3 2018), and $4.0 million (Q4 2017).